Compare MTRX & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTRX | RCEL |
|---|---|---|
| Founded | 1984 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.2M | 306.5M |
| IPO Year | 1995 | 2018 |
| Metric | MTRX | RCEL |
|---|---|---|
| Price | $9.95 | $11.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $17.00 | $7.88 |
| AVG Volume (30 Days) | ★ 324.0K | 270.4K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.51 | 27.20 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $873,632,000.00 | $71,610,000.00 |
| Revenue This Year | $19.75 | $17.17 |
| Revenue Next Year | $7.96 | $49.82 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.56 | 11.45 |
| 52 Week Low | $9.70 | $3.22 |
| 52 Week High | $15.97 | $11.39 |
| Indicator | MTRX | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 30.58 | 61.18 |
| Support Level | $9.79 | $3.64 |
| Resistance Level | $12.69 | $10.77 |
| Average True Range (ATR) | 0.39 | 0.51 |
| MACD | -0.05 | -0.23 |
| Stochastic Oscillator | 11.87 | 32.40 |
Matrix Service Co provides engineering, fabrication, construction, and maintenance services supporting critical energy infrastructure and industrial markets. Its reportable segments are Storage and Terminal Solutions, Utility and Power Infrastructure, and Process and Industrial Facilities, with Storage and Terminal Solutions generating the maximum revenue. This segment provides integrated EPC, repair, maintenance, and fabrication services for bulk liquid, cryogenic, and refrigerated storage and terminal facilities supporting traditional and emerging energy markets, including LNG, NGLs, petroleum products, chemicals, hydrogen, and ammonia, and manufactures specialty tank products. The majority of revenue is generated from the United States.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.